Document is current
Any future updates will be listed below
-
Authors
O’Flaherty, Katherine
Oo, Win Han
Zaloumis, Sophie G.
Cutts, Julia C.
Aung, Kyaw Zayar
Thein, Myat Mon
Drew, Damien R.
Razook, Zahra
Barry, Alyssa E.
Parischa, Naanki
Zaw, Nyi Nyi
Thu, Htin Kyaw
Thi, Aung
Htay, Wai Yan Min
Soe, Aung Paing
Simpson, Julie A.
Beeson, James G.
Agius, Paul A.
Fowkes, Freya J. I.
-
Funding
Funding for this research was provided by:
Three millenium development goal fund (BI-MARC-3MDG-C2-14-00089847)
Australian Research Council (FT130101122)
National Health and Medical Research Council (1134989, 1166753, 1104975, 1173046, 1092789)
- License Information
-
More Information
Article History
Received: 19 November 2020
Accepted: 27 April 2021
First Online: 28 May 2021
Declarations
:
: The primary trial is registered in the Australian New Zealand Clinical Trials Registry (ACTRN12616001434482; approved retrospectively 14 October 2016) and was approved by the Ethics Review Committee on Medical Research involving Human Subjects, Department of Medical Research, Ministry of Health and Sports, Myanmar Government (#21/Ethics/2015; extended approval #Ethics/DMR/2016/020), and the Alfred Hospital, Melbourne, Australia (95/15). The ethics review committee of the Department of Medical Research, Ministry of Health and Sports, requested that there be no commercial advantage for the product during the trial. Consequently, the repellent was provided in plain unbranded tubes, and the investigators registered the trial after completion of fieldwork (but prior to the commencement of data analysis) to minimise public disclosure. The study protocol has been published previously [], and the study is reported according to the CONSORT guidelines of reporting a stepped-wedge cluster randomised trial [].
: The authors declare that they have no competing interests.
